<code id='E711763163'></code><style id='E711763163'></style>
    • <acronym id='E711763163'></acronym>
      <center id='E711763163'><center id='E711763163'><tfoot id='E711763163'></tfoot></center><abbr id='E711763163'><dir id='E711763163'><tfoot id='E711763163'></tfoot><noframes id='E711763163'>

    • <optgroup id='E711763163'><strike id='E711763163'><sup id='E711763163'></sup></strike><code id='E711763163'></code></optgroup>
        1. <b id='E711763163'><label id='E711763163'><select id='E711763163'><dt id='E711763163'><span id='E711763163'></span></dt></select></label></b><u id='E711763163'></u>
          <i id='E711763163'><strike id='E711763163'><tt id='E711763163'><pre id='E711763163'></pre></tt></strike></i>

          Home / hotspot / leisure time

          leisure time


          leisure time

          author:explore    Page View:218
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In